OICR
Ontario Institute
for Cancer Research

TRANSFORMATIVE PATHOLOGY

Dr. John Bartlett, Program Director

PROGRAM HIGHLIGHTS

- Focus on delivering diagnostics to patients via commercialization and dissemination;
- Team is developing, validating, and implementing modern diagnostic methods for routine use in pathology labs and services;
- Extensive experience in contributing to ASCO CAP and European diagnostic guidelines and quality assurance routines;
- Program works extensively in large Phase III clinical trials, including access to approximately 20,000 curated trial samples (breast);
- Close links to the Ontario Tumour Bank;
- 20-member team that includes internationally-recognized expertise in biomarker discovery and validation;
- Interest and experience in developing *in situ* and molecular assays including pathway analysis for validation of biomarkers;
- Ability to produce Level 1 evidence for biomarker validation;
- Ability to support FDA submissions (GLP procedures);
- Numerous successful examples and outcomes associated with working with the diagnostics industry and biotech companies.

MISSION

To develop personalized diagnostic tests that will enable the delivery of modern diagnostic medicine to patients.

FEATURED PROJECTS

VALIDATION OF BIOMARKERS FOR ANTHRACYCLINE SENSITIVITY IN BREAST CANCER

Through meta-analysis of four adjuvant breast cancer trials, we have studied CEP17 duplication, HER2 amplification, and combined TOP2A amplification and deletion in relation to prediction of responsiveness to anthracycline-based chemotherapy

DEVELOPMENT OF BIOMARKERS AND CLINICAL TRIALS ASSOCIATED WITH RISK STRATIFICATION IN BREAST CANCER

We have completed a study that provides evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. The study was the first to reveal a possible association with outcome regardless of node status and ER-negative tumours. Along with data generated in other studies, our analysis further supports this antibody panel's use as a patient management aid in early-stage breast cancer.

OTHER PROJECTS

- Development of the UK OPTIMA (Optimal Personalised Treatment of breast cancer usIng Multi-parameter Analysis) trial to validate use of prognostic markers in treatment selection;
- Novel approaches to mutational and pathway analysis – e.g., development of PI3K/RAS pathway profiling in early breast cancer;
- Key drug resistance pathways for diagnostic and therapeutic targeting through identification of isogenic cell lines.

COLLABORATIVE OPPORTUNITIES

The Program is seeking partners who wish to collaborate to evaluate and validate diagnostic markers, panels and assays to accelerate their dissemination to market. The team is open to working with academic, pharma, or biotech partners who are interested in helping benefit patients in this area.

Contact

For more information please contact:
jane.sun@oicr.on.ca

For commercialization opportunities please contact:
commercialization@oicr.on.ca

Visit us on the web at
oicr.on.ca

Ontario

Funding for OICR is provided by the Government of Ontario